-DOCSTART- -X- O
Vaccination -X- _ O
continues -X- _ O
to -X- _ O
be -X- _ O
the -X- _ O
main -X- _ O
approach -X- _ O
to -X- _ O
protect -X- _ O
animals -X- _ O
from -X- _ O
infectious -X- _ O
diseases. -X- _ O
Until -X- _ O
recently -X- _ O
, -X- _ O
all -X- _ O
licensed -X- _ O
vaccines -X- _ O
were -X- _ O
developed -X- _ O
using -X- _ O
conventional -X- _ O
technologies. -X- _ O
Subunit -X- _ O
vaccines -X- _ O
are -X- _ O
, -X- _ O
however -X- _ O
, -X- _ O
gaining -X- _ O
attention -X- _ O
from -X- _ O
researchers -X- _ O
in -X- _ O
the -X- _ O
field -X- _ O
of -X- _ O
veterinary -X- _ O
vaccinology -X- _ O
, -X- _ O
and -X- _ O
among -X- _ O
these -X- _ O
, -X- _ O
virus-like -X- _ B-Intervention
particles -X- _ I-Intervention
( -X- _ I-Intervention
VLPs -X- _ I-Intervention
) -X- _ I-Intervention
represent -X- _ O
one -X- _ O
of -X- _ O
the -X- _ O
most -X- _ O
appealing -X- _ O
approaches. -X- _ O
VLPs -X- _ B-Intervention
are -X- _ O
robust -X- _ O
protein -X- _ O
cages -X- _ O
in -X- _ O
the -X- _ O
nanometer -X- _ O
range -X- _ O
that -X- _ O
mimic -X- _ O
the -X- _ O
overall -X- _ O
structure -X- _ O
of -X- _ O
the -X- _ O
native -X- _ O
virions -X- _ O
but -X- _ O
lack -X- _ O
the -X- _ O
viral -X- _ O
genome. -X- _ O
They -X- _ O
are -X- _ O
often -X- _ O
antigenically -X- _ O
indistinguishable -X- _ O
from -X- _ O
the -X- _ O
virus -X- _ O
from -X- _ O
which -X- _ O
they -X- _ O
were -X- _ O
derived -X- _ O
and -X- _ O
present -X- _ O
important -X- _ O
advantages -X- _ O
in -X- _ O
terms -X- _ O
of -X- _ O
safety. -X- _ O
VLPs -X- _ B-Intervention
can -X- _ O
stimulate -X- _ B-Outcome
strong -X- _ I-Outcome
humoral -X- _ I-Outcome
and -X- _ I-Outcome
cellular -X- _ I-Outcome
immune -X- _ I-Outcome
responses -X- _ I-Outcome
and -X- _ I-Outcome
have -X- _ I-Outcome
been -X- _ I-Outcome
shown -X- _ I-Outcome
to -X- _ I-Outcome
exhibit -X- _ I-Outcome
self-adjuvanting -X- _ I-Outcome
abilities. -X- _ I-Outcome
In -X- _ O
addition -X- _ O
to -X- _ O
their -X- _ O
suitability -X- _ O
as -X- _ O
a -X- _ O
vaccine -X- _ O
for -X- _ O
the -X- _ O
homologous -X- _ O
virus -X- _ O
from -X- _ O
which -X- _ O
they -X- _ O
are -X- _ O
derived -X- _ O
, -X- _ O
VLPs -X- _ B-Intervention
can -X- _ O
also -X- _ O
be -X- _ O
used -X- _ B-Outcome
as -X- _ I-Outcome
vectors -X- _ I-Outcome
for -X- _ O
the -X- _ O
multimeric -X- _ O
presentation -X- _ O
of -X- _ O
foreign -X- _ O
antigens. -X- _ O
VLPs -X- _ B-Intervention
have -X- _ O
therefore -X- _ O
shown -X- _ B-Outcome
dramatic -X- _ I-Outcome
effectiveness -X- _ I-Outcome
as -X- _ O
candidate -X- _ O
vaccines. -X- _ O
Here -X- _ O
, -X- _ O
we -X- _ O
review -X- _ O
the -X- _ O
current -X- _ O
status -X- _ O
of -X- _ O
VLPs -X- _ O
as -X- _ O
a -X- _ O
vaccine -X- _ O
technology -X- _ O
in -X- _ O
the -X- _ O
veterinary -X- _ O
field -X- _ O
, -X- _ O
and -X- _ O
discuss -X- _ O
the -X- _ O
potential -X- _ O
advantages -X- _ O
and -X- _ O
challenges -X- _ O
of -X- _ O
this -X- _ O
technology -X- _ O
. -X- _ O

